Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Introduction Cenerimod is an orally available and potent sphingosine-1-phosphate receptor 1 (S1P1) modulator, which is a class of drugs that triggers sustained receptor internalization, blocks the egress of lymphocytes from lymphoid organs and, thereby, reduces tissue availability of circulating lymphocytes.1-3 The pharmacodynamic (PD) effect of cenerimod is dose-dependent and sustained with continued once-daily (o.d.) dosing but is reversible upon drug discontinuation.4, 5 Cenerimod is a...
This is an early access version, the complete PDF, HTML, and XML versions will be available soon. Open AccessArticle by Pierre-Eric Juif 1, Markus S. Mueller 1, Hakim Charfi 2 and Jasper Dingemanse 1,* 1 Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd., Hegenheimermattweg 91, 4123 Allschwil, Switzerland 2 Biotrial, 7–9 Rue Jean-Louis Bertrand, 35000 Rennes, France * Author to whom correspondence should be addressed. Int. J. Mol. Sci.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
